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To the Editor
Since the immunomodulatory properties of probiotics have
been described, the effect of probiotic supplementation has
been investigated in several trials and it has been also pro-
posed as a preventive intervention for the development of
allergic diseases. Recently two important evidence-based
recommendations about the use of probiotics in the pre-
vention of allergy were published [1, 2] with conflicting
conclusions, in particular the most recent guideline [1]
seems to be partially in contradiction with the previous
statements about prevention of eczema. For these reasons,
we tried to analyze the evidences leading to these recom-
mendations [1] to highlight the aspects that can be more
directly related or correlated with clinical practice. This
clinical reading was addressed to offer some reflections
about the methods used to formulate such recommenda-
tions, and the possibility to adopt in the clinical practice the
proposed conclusions.
We tried to retraces the path proposed by the Authors
to analyse three important questions about the efficacy
of probiotics in preventing allergic diseases if adminis-
trated to pregnant women (first question), to breastfeed-
ing mothers (second question) and in healthy infants
(third question).
These questions have been investigated by using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach [3], to perform a sys-
tematic review of randomized controlled trials and for-
mulate recommendations. In summary, the GRADE
method aims to define a rigorous and explicit method
for the production of clinical recommendations. Accord-
ing to this method, the knowledge of advantages and
disadvantages, benefits and risks of an intervention is
necessary to make decisions in the health field. The
GRADE approach also provides a three-phases deci-
sional framework: a) formulation of a clinical question,
with the choice and the formal evaluation of its related
outcomes, and systematic evaluation of the scientific lit-
erature and the quality of the evidence; b) evaluation of
the benefits and risks associated to the intervention, tak-
ing also in consideration its feasibility, the necessary re-
sources and the patients’ preferences; c) formal
definition of the strength of the recommendation.
From a methodological point of view, it should be
noted that the recommendations are directed to pa-
tients, clinicians and other health care professionals with
different objectives, as clearly explained in the guidelines
introduction. Each recommendation can have different
levels of strength: strong recommendation indicates that
patients would like to receive the intervention and that
clinicians should actuate it. Conditional or weak recom-
mendation indicates that the majority of patients would
like to receive the intervention, but many other not, as
well as they hope that clinicians would recognize that
different choices may be appropriate for different pa-
tients, by taking advantage of decision-making tools to
help patients to make consistent choices.
In the results section of the guidelines we can read that
“Currently available evidence does not indicate that pro-
biotic supplementation reduces the risk of developing
* Correspondence: giampaolo.ricci@unibo.it
8Pediatric Unit, Department of Medical and Surgical Sciences, University of
Bologna, S. Orsola-Malpighi Hospital, Pad 16, via Massarenti 11, 40138
Bologna, Italy
Full list of author information is available at the end of the article
© 2016 Ricci et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ricci et al. World Allergy Organization Journal  (2016) 9:9 
DOI 10.1186/s40413-016-0101-8
allergy in children. However, considering all critical out-
comes in this context, the World Allergy Organization
(WAO) guideline panel determined that there is a likely net
benefit from using probiotics resulting primarily from pre-
vention of eczema” [1].
In the first sentence, the guideline panel confirmed the
absence of evidence of effectiveness in the use of probio-
tics in the primary prevention of the common allergic
diseases (asthma, food allergy, rhinitis). The second
sentence deserves a careful review, because it seems to
contradict the meaning of the first sentence and the pos-
ition of the other guidelines, including the recent Euro-
pean Academy of Allergy and Clinical Immunology
(EAACI) guideline [2].
In order to comment this phrase, we started from the
description of the evidences (GRADE) in Appendix 2 -
Question 1: “Should probiotics vs. no probiotics be used
in pregnant women?” In this appendix we can found de-
clared how many studies addressing this question have
been selected for each of the clinical objectives: 15 ran-
domized trials were considered for the prevention of
eczema.
The comment of this question can be also reliable if it is
applied to the other two questions above, as approximately
the same studies have been selected for critical review.
In this regard, we carefully examined the individual trials
to better analyze and understand the results of the ques-
tion. The most important clinical features that supported
our considerations are reported in Table 1 and Table 2.
A preliminary observation about the 15 trials above
[4–18] is that they are all randomized against placebo,
they were published between 2001 and 2012, that is a
rather brief period to be well compared. It should be
mentioned that the study of Rautava et al. (2002) [5]
analyzes a subset of patients previous described by
Kalliomaki et al. (2001) [4], as well as Marschan et al.
(2008) [9] analyzed a subgroup of patients described
by Kukkonen et al. (2007) [7].
Almost all studies identified patients with family history
of atopy as targets for treating, indicating that children at
high risk of atopy should be the potential beneficiaries of a
preventive intervention with probiotic supplementation.
The total number of subjects included in the trials is
relevant, but the type of probiotic or association of pro-
biotics used is widely different among the studies. As the
Authors underlined, we have to face a "heterogeneity of
the interventions and limitations in reporting of original
studies”, so it was not possible to analyze neither the ef-
fects in each group separately nor the effects of individ-
ual probiotic species.
This statement is clearly expressed in the guideline, but
it deserves some particular considerations. The term
probiotic currently includes bacteria associated with bene-
ficial effects; according to the World Health Organization
definition [19], the term probiotics refers to “live micro-
organisms which, when administered in adequate
amounts, confer a health benefit on the host". Probiotics
may act by different mechanisms, as well as the Authors
have pointed out, that means it is important to consider
also if the action is the same or if there are differences of
action between the different probiotics used in the differ-
ent trials. Since a wide literature is available on probiotics,
we can take for example the data related to Lactobacillus
rhamnosus, the most used probiotic species.
A recent trial examined 100 strains of Lactobacillus
rhamnosus isolated from different food sources and hab-
itats from the human body (mouth, bowel, vagina) [20]
by carrying out a genomics and functional comparative
analysis. A wide spectrum of phenotypes with different
functional properties, which have been grouped by the
Authors according to the two most common geno-
phenotypes (A and B). The geno-phenotype A seems
to be related permanently to a greater ability to adapt
to nutrient-rich foods such as dairy products, but also
to the loss of some biological functions involved in
the antimicrobial activity, in the resistance and ability
to adapt to different habitats. The geno-phenotype B
shows a greater ability to adapt to different habitats
and resources with different nutrients and different
effects on the host.
A recent study analyzed the relationship between den-
tal caries and Lactobacillus rhamnosus, showing a likely
causal role of two strains: Lactobacillus rhamnosus
LRHMDP2 and LRHMDP were isolated in the dental
pulp, furthermore the analysis of their genes showed dif-
ferences with the probiotic Lactobacillus rhamnosus GG
(ATCC 53103) which does not seem implicated in the
pathogenesis of dental caries [21].
Also a comparison between Lactobacillus strains iso-
lated from dairy products market of Lactobacillus rhamno-
sus GG (ATCC53103), Lactobacillus rhamnosus LRV,
Lactobacillus rhamnosus LRI, Lactobacillus casei BL23
(ATCC393), Lactobacillus casei LCY, and Lactobacillus
casei LCA showed different genomic profiles, as well as dif-
ferent functional capabilities in glucose metabolism and in
the ability to adhere to intestinal mucus [22]. As the Au-
thors also point out, we believe that this evidence is a crit-
ical point for the definition of the quality of the evidence,
described as very low.
In the selected studies, different strains have been used
in various combinations: it is necessary to consider differ-
ent mechanisms of action and possible interactions in the
bowel, in addition to the different effects of different com-
binations of micro-organisms. The species Lactobacillus
rhamnosus GG (ATCC 55103) is the most widely studied
probiotic, both alone and in combination, but the data
only from studies that use this type of probiotic would be
insufficient.
Ricci et al. World Allergy Organization Journal  (2016) 9:9 Page 2 of 8
The duration of treatment in the late pregnancy is
fairly homogeneous across all studies, and it varies from
2 to 6 weeks before the expected date of birth.
Among the 15 selected studies, we considered the
main clinical features associated with the diagnosis of
eczema useful to analyze the question 1 of the guideline
and we reported them in Table 2. The predominant dur-
ation of follow-up was 24 weeks, a sufficient period to
evaluate the appearance of atopic dermatitis, since in
most cases it begins within 24 months of life. The
criteria used for the diagnosis of atopic eczema are the
most widely recognized in the literature: Hanifin and
Rajka criteria [23] and the UK-Working Party’s criteria
[24]. The number of patients with a complete follow-up
usually exceed the 80 % of the enrolled patients, so the
quality of the available data seems to be very good for
the statistical analysis.
It is more difficult to evaluate the results on the occur-
rence of eczema with its two clinical phenotypes: the
IgE-associated and non IgE-associated, which differ both
Table 1 Characteristics of the 15 trials included in the meta-analysis and addressing the guideline’s Question 1: “Should probiotics















et al. 2001 [4]
yes 159 Lactobacillus rhamnosus GG (ATCC 55103) 2-4 weeks 6 months 6 months
Rautava et al.
2002 [5]a
yes 62 Lactobacillus rhamnosus GG (ATCC 53103) 4 weeks 3 months 3 months
Abrahamsson
et al. 2007 [6]
yes 232 Lactobacillus reuteri (ATCC55730) 4 weeks 12 months 12 months
Kukkonen
et al. 2007 [7]
yes 1223 Lactobacillus rhamnosus GG (ATCC 55103),
Lactobacillus rhamnosus LC705 (DSM7061),
Bifidobacterium breve Bb99 (DSM13692),
Propionibacterium freudenreichiii ssp shermanii JS
(DSM7076)
2-4 weeks 6 months 6 months
Huurre et al.
2008 [8]
yes 171 Lactobacillus rhamnosus GG (ATCC 55103)
Bifidobacterium lactis Bb12




et al. 2008 [9]b
yes 98 Lactobacillus rhamnosus GG (ATCC 55103),
Lactobacillus rhamnosus LC705 (DSM7061),
Bifidobacterium breve Bb99 (DSM13692),
Propionibacterium freudenreichiii ssp shermanii JS
(DSM7076)
2-4 weeks 6 months 6 months
Wickens et al.
2008 [10]
yes 512 Lactobacillus rhamnosus HN001, Bifidobacterium
animalis subspec lactis HN019
5 weeks 6 months 24 months
Kopp et al.
2008 [11]
yes 105 Lactobacillus rhamnosus GG ( ATCC 53103) 4-6 weeks 6 months 6 months
Niers et al.
2009 [12]
yes 156 Bifidobacterium bifidum W23, Bifidobacterium lactis
W52Lactococcus lactis W58
6 weeks 12 months
Dotterud
et al. 2010 [13]
no 415 Lactobacillus rhamnosus GG, Bifidobacterium animalis
subsp.Bb-12, Lactobacillus acidophilus La-5
4 weeks 3 months
Kim et al.
2010 [14]
yes 112 Bifidobacterium bifidum BGN4, Bifidobacterium lactis
AD011, Lactobacillus acidophilus AD031
8 weeks 3 months 4-6 months
Boyle et al.
2011 [15]











454 Lactobacillus salivarius CUL61, Lactobacillus paracasei
CUL08, Bifidobacteriums animalis ssp. lactis CUL34,
Bifidobacterium bifidum CUL20
4 weeks 6 months 6 months
Rautava et al.
2012 [18]
yes 241 Lactobacillus rhamnosus LP + Bifidobacterium longum
(ATCC BAA-999) or Lactobacillum paracasei ST11 +
Bifidobacterium longum (ATCC BAA-999 )
2 months 2 months
aAnalysis of a subgroup of patients previous analyzed by Kalliomaki et al. [4]
bAnalysis of a subgroup of patients previous analyzed by Kukkonen et al. [7]
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Table 2 Main clinical characteristics related to the diagnosis of eczema in 15 trials included in the meta-analysis for the guideline’s Question 1: “Should probiotics vs. no probio-













Persistence of eczema Allergic sensitization
PROBIOTIC PLACEBO P value % P value
Kalliomaki et al. 2001 [4] 24 Harrigan 1999 64/77
68/82 (Pl)
15/64 23 % 31/68 46 % 0.008 (sIgE) 27 % vs 25 % (Pl)
(SPT) 18 % vs 14 % (Pl)
NS
NS
Rautava et al. 2002 [5]a 24 Harrigan 1999 32
30 (Pl)
4/27 15 % 14/30 47 % 0.0098 (sIgE) 28 % vs 37 % (Pl)
(SPT) 23 % vs 21 % (Pl)
NS
NS








(sIgE) 37 % vs 48 %
(SPT) 18 % vs 29 %
NS
NS









28 % vs 31.2 (Pl)
NS
Huurre et al. 2008 [8] 12 H-R 7268 (Pl) 9.7 % 17.6 % NS 29 % vs 31 % (Pl)
Subgroup with maternal
sensitization.
26 % vs 50 % (Pl)
NS
0.023
Marschan et al. 2008 [9]b 24 UK-WP 52
46 (Pl)
31 % 39 % (sIgE) 35 % vs 26 % (Pl)














(SPT) Lrha 21.3 %
eBl 23.5 % vs 28.8 % (Pl)
NS
Kopp et al. 2008 [11] 24 UK-WP 50/54
44/51 (Pl)
28 % 27.3 % NS (sIgE to inhalants)
8 % vs 11.3 % (Pl)
NS
Niers et al. 2009 [12] 24 H-R 50/78
48/78 (Pl)
(Questionnaire)
3 months 12 %
24 months 54 %
(Clinical)
3 months 6 %
IgE-eczema 20 %
(Questionnaire)
3 months 29 %
24 months 68.7 %
(Clinical)







20 % vs 14.6 % (Pl)
NS




Non IgE-Eczema 13 %
34.3 %
IgE-Eczema 7.5 %





15.3 % vs 11.3 % (Pl)
NS








(sIgE) 38.7 % vs 51.7 % (Pl) NS
Boyle et al. 2011 [15] 12 UK-WP 109/125
103/125 (Pl)













Table 2 Main clinical characteristics related to the diagnosis of eczema in 15 trials included in the meta-analysis for the guideline’s Question 1: “Should probiotics vs. no probio-
tics be used in pregnant women?”. (Continued)
Ou et al. 2012 [16] 36 65/95
63/96 (Pl)
6 months 3.3 %
18 months 25 %
36 months 24.6 %
6 months 23.6 %
18 months 17.7 %





47.7 % vs 46.9 % (Pl)
NS








10.5 % vs 18.5 % 0.036
Rautava et al. 2012 [18] 24 H-R 73/81 (Lrha)
70/82 (Lpar)
62/78 (Pl)
29 % (10 %)*
29 % (6 %)*






H-R: Hanifin and Rajka; UK-WP: UK Working Party; Harrigan 1999: Harrigan’s criteria [28]; Lrha: Lactobacillus rhamnosus; Bl: Bifidobacterium lactis; Lpar: Lactobacillus paracasei; Pl: Placebo; SPT: skin prick test; sIgE:
specific IgE
aAnalysis of a subgroup of patients previous analyzed by Kalliomaki et al. [4]
bAnalysis of a subgroup of patients previous analyzed by Kukkonen et al. [7]













in the clinical features and in the evolution toward other
allergic diseases. IgE-associated forms are more prone to
the evolution in allergic rhinitis and asthma, especially if
there is also a clear sensitization to inhalant allergens.
The data shown in Table 2 at the end of follow-up
period include 13 trials, excluding the two trials above
mentioned [5, 9] that analyzed subsets of patients of
broader studies [4, 7]. Among these, 6 studies [4, 7, 10,
13, 14, 18] showed a significant reduction in the rate of
occurrence of eczema in the group treated with probiotics
if compared with placebo group, while the other 8 studies
[6, 8, 10–12, 15–17] didn’t show significant differences be-
tween the two groups. The study of Wickens et al. [10] is
considered twice as the group receiving Lactobacillus
rhamnosus HN001 was statistically significant while that
one treated with Bifidobacterium animalis lactis subspec
HN019 was not significant.
In 7 of these trials, the analysis can be restricted to the
appearance of IgE-associated eczema: 4 studies showed a
statistical significance [6, 7, 10, 17], while 4 studies [10,
12–14] didn’t show significant differences (the study of
Wickens et al. [10] was considered twice).
Finally, the analysis of the presence of allergic
sensitization assessed by specific IgE and/or skin prick test
provided significant results only in two cases, while in 13
others it was not statistically significant.
Another important issue discussed in this guideline is
the detection of adverse effects. The analysis took into
consideration also an extensive review of a study carried
out by the Health Assessment Technology [25], which
did not report significant adverse effects and in any case,
it did not describe an increased risk, despite some limi-
tations indicated in the study. Lastly, the adverse events
reported in these 15 trials are mild and short-term
events, without substantial clinical differences between
the groups receiving probiotics and those receiving
placebo.
Conclusions
This guideline indicates the lack of clear evidence of ef-
ficacy of probiotic supplementation in the primary pre-
vention of allergies. In the recommendation 1, the WAO
guideline panel suggests "using probiotics in pregnant
women at high risk for allergy in their children, because
considering all critical outcomes, there is a net benefit
resulting primarily from prevention of eczema (condi-
tional recommendation, very low quality evidence)”; in the
case of eczema this recommendation is also provided re-
garding the other two clinical questions.
The low number of reported adverse effects confirms a
high safety profile. The "net benefit" highlighted in the
prevention of eczema appears to be overly optimistic
when considering the wide heterogeneity of interventions
and the inconsistence of the results in the statistical
analysis. However, the GRADE system takes into account
aspects that are helpful to "support each person in reach-
ing a management decision consistent with his/her values
and preferences" [3]. Nevertheless, although we cannot ex-
clude the possibility of using probiotics in special situa-
tions, such as an important family history of atopic
eczema, the extension and the generalization of their use
does not seem to be sufficiently supported by scientific
evidence.
Eczema and allergic diseases represent a complex puzzle
in which many factors interact. It is often difficult to sep-
arate the various factors involved, also because some of
their effects may develop after a long time and are difficult
to demonstrate. The guideline provides an important sci-
entific synthesis that allows us to highlight the limitations
of certain studies, but at the same time to get good points
for further research. The time to suggest that preventive
approach in a generalized way has not yet come, but these
findings may be the starting point to search for more solid
evidence and for new trials.
Author’s response to “A clinical reading on “World Allergy
Organization-McMaster University Guidelines for Allergic
Disease Prevention (GLAD-P): Probiotics”
Cuello-Garcia CA, Brożek JL, Fiocchi A, Pawankar R,
Yepes-Nuñez JJ, Terracciano L, Gandhi S, Agarwal A,
Zhang Y, Schünemann HJ
We would like to thank Drs. Ricci and Cipriani for their
insightful comments on the World Allergy Organization
(WAO) guideline for the prevention of allergies with pro-
biotics. In their letter, Drs. Ricci and Cipriani raised three
concerns calling for additional clarification:
a. the discrepancy in the conclusions between the
WAO [1] and the European Academy of Allergy and
Clinical Immunology (EAACI) guidelines [2]
regarding the use of probiotics;
b. the possibility to generalize recommendations to use
probiotics when children are not at high risk of
developing allergy; and
c. a possibly “overly optimistic” assessment of benefits
in the face of heterogeneity of interventions and
inconsistency of the results in the analysis.
The main focus of the EAACI guidelines was on
prevention of food allergy, whereas the WAO guidelines
focused on a broader question whether or not probiotics
should be used in the context of prevention of any
allergy in otherwise healthy infants. The WAO and
EAACI experts’ conclusion about the paucity of evidence
was the same – both found not enough published evi-
dence to confirm or reject an effect of probiotic supple-
mentation on development of food allergy in infants.
However, in order to provide advice whether or not to
Ricci et al. World Allergy Organization Journal  (2016) 9:9 Page 6 of 8
use probiotics for the prevention of allergy, the WAO
guideline panel considered all outcomes important to
patients and their caregivers in this context. Those
included development of food allergy but also other out-
comes deemed by the WAO panel to be important:
development of wheezing and/or asthma, allergic rhinitis,
eczema, urticaria and anaphylaxis, nutrition status, infec-
tion with probiotic bacteria and other adverse effects.
WAO advice to use probiotics in pregnant women,
breastfeeding mothers and infants at high risk of devel-
oping an allergy was explicitly based on the likely lower
risk of developing eczema. The recommendation stated,
“….there is a net benefit resulting primarily from preven-
tion of eczema” and that “…there is lack of evidence that
probiotics prevent any other allergy”. This was a condi-
tional recommendation meaning that clinicians should
recognize that different choices would be appropriate for
different individuals, often depending on their values
and preferences. The WAO guideline panel, again expli-
citly, informed that the evidence supporting this advice was
of very low quality, meaning that the panel was very uncer-
tain how probiotic supplementation would actually affect
all outcomes of interest. This implies that any further re-
search – if done – is very likely to change both the strength
and even the direction of those recommendations.
Drs. Ricci and Cipriani also expressed a concern about
the possibility of broadening the recommendations to
use probiotic supplementation to situations when infants
would be at low risk of developing allergies. The WAO
guideline panel was again very explicit suggesting using
probiotics in infants at high risk. Usually, one can ex-
trapolate from the evidence in high-risk populations to
lower risk groups with additional uncertainty about the
expected effects introduced by the lack of direct evi-
dence. In the case of WAO recommendations, the
guideline panel thought that this additional extrapolation
from already indirect evidence would make any informa-
tion too unreliable to support an informed advice for
low risk situations.
The last comment is in relation to a possibly “overly
optimistic” assessment of net benefits from probiotic
supplementation in the face of heterogeneity of probio-
tics used in the studies and inconsistency of the results
in the analysis. Dr. Szajewska and colleagues have previ-
ously expressed similar concerns whether the effect of
probiotics on preventing eczema is a class effect or if
one probiotic might have better efficacy than others
might [26]. We share these concerns and agree that a
conclusion that all probiotics are equal would be prema-
ture. However, the available data from randomized trials
do not exclude the possibility of either a class effect or a
true difference among the probiotic strains in their ef-
fects in prevention of eczema. This very inconsistency in
the results among studies and other limitations resulted
in previously mentioned very low confidence in the ef-
fects of probiotics [27].
We agree with Drs. Ricci and Cipriani that more re-
search evidence is needed. Until it becomes available,
parents and clinicians will need to make decisions under
uncertainty about the true balance of benefits and down-
sides of using probiotic supplementation in pregnant
women, breastfeeding mothers and infants with the
intention to prevent allergies.
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